Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hynson, Westcott & Dunning
Baltimore, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Lutrexin, a product for women's health indications, was withdrawn by FDA due to lack of adequate evidence for efficacy following the 1962 amendments requiring effectiveness as well as safety. The company challenged this withdrawal, resulting in a Supreme Court hearing on due process for regulatory drug approvals.
- Therapeutic areas
- Women's Health
- Modalities
- Small molecule
- Industry
- Pharma
Beyond the preview
Go deeper on Hynson, Westcott & Dunning.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hynson, Westcott & Dunning.